Stuttgart
30.06.25 | 07:43
60,50 Euro
0,00 % 0,00
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.06. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 8 | GlobeNewswire (USA) | ||
| 23.06. | Novonesis (Novozymes A/S): Major shareholder announcement | 7 | GlobeNewswire (USA) | ||
| 19.06. | Novonesis (Novozymes A/S): Major shareholder announcement | 3 | GlobeNewswire (USA) | ||
| 16.06. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 3 | GlobeNewswire (USA) | ||
| 12.06. | Novonesis (Novozymes A/S): Major shareholder announcement | 6 | GlobeNewswire (USA) | ||
| NOVONESIS A/S ADR Aktie jetzt für 0€ handeln | |||||
| 10.06. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 2 | GlobeNewswire (USA) | ||
| 10.06. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 3 | GlobeNewswire (USA) | ||
| 02.06. | DSM-Firmenich schliesst Verkauf von Feed Enzymes Alliance an Novonesis ab | 30 | cash | ||
| 02.06. | dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion | 511 | GlobeNewswire (Europe) | Press Release
dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion
Kaiseraugst (Switzerland), Maastricht (Netherlands), June 2, 2025
dsm-firmenich... ► Artikel lesen | |
| 02.06. | Novonesis (Novozymes A/S): Novonesis completes acquisition of dsm-firmenichs's share of the Feed Enzyme Alliance | 4 | GlobeNewswire (USA) | ||
| 02.06. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 3 | GlobeNewswire (USA) | ||
| 29.05. | Morgan Stanley stuft Novonesis-Aktie mit Kursziel von 577,00 DKK als Overweight ein | 8 | Investing.com Deutsch | ||
| 29.05. | Morgan Stanley sets Novonesis stock Overweight with DKK577 target | 4 | Investing.com | ||
| 29.05. | MS starts Novonesis at Overweight, says stock to rerate towards its prior highs | 2 | Investing.com | ||
| 28.05. | UBS upgrades Novonesis to "buy," cuts Kerry to "neutral" on growth outlook | 3 | Investing.com | ||
| 27.05. | UBS lifts Novonesis stock rating to Buy, target to DKK530 | 5 | Investing.com | ||
| 27.05. | UBS hebt Novonesis-Bewertung auf Kaufen an, Kursziel auf 530 DKK | 5 | Investing.com Deutsch | ||
| 26.05. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 2 | GlobeNewswire (USA) | ||
| 19.05. | Novonesis (Novozymes A/S): Combining EVP roles of Human Health Biosolutions and Strategy & Integration | 4 | GlobeNewswire (USA) | ||
| 19.05. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 5 | GlobeNewswire (USA) |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GENMAB | 176,90 | +0,77 % | Genmab A/S: Transactions in Connection with Share Buy-back Program | ||
| INSMED | 84,50 | -0,59 % | Insmed Incorporated: Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension | -The Study Met Primary and All Secondary Efficacy Endpoints-
Statistically Significant 35% Placebo-Adjusted Reduction from Baseline in Pulmonary Vascular Resistance... ► Artikel lesen | |
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -6,35 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen |
NOVONESIS A/S ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,00 (0,00 %) liegt der Kurs bei 60,50 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NOVONESIS A/S ADR finden Sie auf Wallstreet Online.